The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Revance Therapeutics competitive analysis

Loading summary...

Latest patents of Revance Therapeutics opposed by its competitors

Explore Revance Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2490986
Apr 24, 2024Methods And Systems For Purifying Non-Complexed Botulinum Neurotoxin1
EP3368071
Jan 26, 2022Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect1
EP2661276
Aug 2, 2017Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions1

Latest PTAB cases involving Revance Therapeutics

Discover the latest PTAB cases involving Revance Therapeutics, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 14, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Revance Therapeutics

IPR2021-01203Jul 1, 2021REVANCE THERAPEUTICSMEDY TOXInstitution Denied
IPR2021-01204Jul 1, 2021REVANCE THERAPEUTICSMEDY TOXInstitution Denied

Peer Comparison New

IP litigation analysis comparing Revance Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
REVANCE THERAPEUTICS - 32 -
ALLERGAN11291333
IPSEN BIOPHARMA2 - - -
MEDY TOX - 2 - 3